Skip to main content

Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.

Publication ,  Journal Article
Clift, RA; Buckner, CD; Thomas, ED; Bryant, E; Anasetti, C; Bensinger, WI; Bowden, R; Deeg, HJ; Doney, KC; Fisher, LD
Published in: Blood
December 15, 1994

The records were reviewed of 58 patients receiving transplants in Seattle with unmanipulated marrow from HLA-identical siblings during the accelerated phase (AP) of chronic myeloid leukemia. Variables examined for association with survival and relapse included the interval from diagnosis to transplant, the reasons for categorization as AP, age, regimen, and cytomegalovirus serology. Four patients relapsed. The 4-year probabilities of survival, relapse-free survival, nonrelapse mortality, and relapse were 0.49, 0.43, 0.51, and 0.12, respectively. After completion of the stepwise multivariate analysis, age less than 38 years and categorization as AP solely on the basis of chromosomal abnormalities emerged as being independently significantly associated with improved survival. The 4-year probability of survival for the 16 patients categorized as AP because of chromosomal abnormalities and receiving transplant less than 1 year from diagnosis was 0.74. The low probability of relapse in these patients suggests that more aggressive preparative regimens are not indicated for patients receiving transplants in AP because of the increased risk of transplant-related mortality.

Duke Scholars

Published In

Blood

ISSN

0006-4971

Publication Date

December 15, 1994

Volume

84

Issue

12

Start / End Page

4368 / 4373

Location

United States

Related Subject Headings

  • Whole-Body Irradiation
  • Washington
  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Splenectomy
  • Spleen
  • Salvage Therapy
  • Retrospective Studies
  • Recombinant Proteins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Clift, R. A., Buckner, C. D., Thomas, E. D., Bryant, E., Anasetti, C., Bensinger, W. I., … Fisher, L. D. (1994). Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood, 84(12), 4368–4373.
Clift, R. A., C. D. Buckner, E. D. Thomas, E. Bryant, C. Anasetti, W. I. Bensinger, R. Bowden, H. J. Deeg, K. C. Doney, and L. D. Fisher. “Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.Blood 84, no. 12 (December 15, 1994): 4368–73.
Clift RA, Buckner CD, Thomas ED, Bryant E, Anasetti C, Bensinger WI, et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 1994 Dec 15;84(12):4368–73.
Clift, R. A., et al. “Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.Blood, vol. 84, no. 12, Dec. 1994, pp. 4368–73.
Clift RA, Buckner CD, Thomas ED, Bryant E, Anasetti C, Bensinger WI, Bowden R, Deeg HJ, Doney KC, Fisher LD. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 1994 Dec 15;84(12):4368–4373.

Published In

Blood

ISSN

0006-4971

Publication Date

December 15, 1994

Volume

84

Issue

12

Start / End Page

4368 / 4373

Location

United States

Related Subject Headings

  • Whole-Body Irradiation
  • Washington
  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Splenectomy
  • Spleen
  • Salvage Therapy
  • Retrospective Studies
  • Recombinant Proteins